Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer

摘要: Epithelial ovarian cancer kills almost 16 000 women each year in part due to late stage of presentation and lack reliable biomarkers for disease detection. CA-125, the currently accepted serum marker, alone lacks sensitivity early diagnosis, as only 50% cases are detected with this marker. Although more may be by lysophosphatidic acid, marker is also elevated other cancers. One major objective NCI-FDA Tissue Proteomics Initiative has been combine technique laser capture microdissection (LCM) epithelial tumor cells human tissue specimens two-dimensional gel electrophoresis (2-D PAGE) identify proteins that serve invasive cancer-specific detection and/or new therapeutic targets. We performed 2-D PAGE on lysates from five microdissected tumors (three cancers two noninvasive, low malignant potential (LMP) tumors). then compared silver stained gels created SYPRO-Ruby profiles patient-matched undissected bulk all patients. Twenty-three were consistently differentially expressed between both LMP three limited study set. Thirteen uniquely present absent or underexpressed cases. Ten but Credentialing preliminary target validation mass spectrometry identified cut Ruby-red was LCM coupled Western blot reverse-phase array technology a set six (the aforementioned used profiling component plus one additional case). The analysis revealed 52 kDa FK506 binding protein, Rho G-protein dissociation inhibitor (RhoGDI), glyoxalase I found overexpressed when form cancer. direct comparison generated proteomic vs. directly generate important markers targets unique phenotype.